Loading…
Precision BioSciences, Inc. is projected to rise to $12.22 by 2027, a +61% move from its current price of $7.59. DTIL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $7.34 | $7.59 | $7.86 | +0.04% |
| May 30 | $7.24 | $7.60 | $7.97 | +0.09% |
| May 31 | $7.16 | $7.60 | $8.07 | +0.13% |
| Jun 1 | $7.10 | $7.60 | $8.14 | +0.18% |
| Jun 2 | $7.05 | $7.61 | $8.21 | +0.22% |
| Jun 3 | $7.00 | $7.61 | $8.28 | +0.27% |
| Jun 4 | $6.95 | $7.61 | $8.34 | +0.31% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.95 | $7.61 | $8.34 | +0.31% |
| Week 2 | $6.72 | $7.64 | $8.68 | +0.62% |
| Week 3 | $6.55 | $7.66 | $8.96 | +0.93% |
| Week 4 | $6.41 | $7.68 | $9.21 | +1.25% |
| Week 5 | $6.29 | $7.71 | $9.44 | +1.56% |
| Week 6 | $6.19 | $7.73 | $9.66 | +1.88% |
| Week 7 | $6.10 | $7.76 | $9.86 | +2.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Precision BioSciences, Inc. is a clinical stage gene editing company that develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.
The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy.
In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion.
Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
DTIL is the stock symbol for Precision BioSciences, Inc. The current price is $7.23 per share and the market cap is $186.55M. It is ranked 3882 by market capitalization.
The forecasted price path shows a clear upside trajectory: the 2026 average price is $7.23, rising to a 2030 average of $16.30 with a 125.4% ROI, a 2040 average of $50.37 with a 596.7% ROI, and a 2050 average of $104.43 with a 1344.4% ROI. The sentiment across the forecast years is bullish from 2027 onward, suggesting meaningful upside potential over the longer term.
These figures reflect the asset’s expected price progression and are not guarantees. The numbers illustrate potential growth embedded in the projected path and should be considered alongside inherent market risks.
A major floor 53.0% below — a decisive break under it would weaken the trend.
The nearest floor, 9.1% below — buyers have tended to step in here.
The nearest ceiling, 9.9% above — a clean break opens room to run.
A major ceiling 19.2% above — clearing it would confirm fresh momentum.
Key DTIL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DTIL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.35 | Buy | $7.43 | Buy |
| MA 10 | $7.43 | Buy | $7.42 | Buy |
| MA 20 | $7.47 | Buy | $7.38 | Buy |
| MA 50 | $7.03 | Buy | $6.88 | Buy |
| MA 100 | $5.63 | Buy | $6.24 | Buy |
| MA 200 | $5.51 | Buy | $5.87 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.17 | Neutral |
| Stoch RSI (14) | 43.59 | Neutral |
| CCI (20) | 23.79 | Neutral |
| Williams %R (14) | -52.08 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -1.30 | Sell |
| Bollinger %B (20,2) | 0.57 | Neutral |
| Stochastic %K (14) | 47.92 | Neutral |
| TRIX (15) | 0.35 | Buy |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 58.55 | Neutral |
| Momentum (10) | -0.61 | Sell |
| Aroon Osc (25) | -16.00 | Sell |
| Hull MA (9) | 7.46 | Buy |
| ADX (14) | 16.26 | Neutral |
| ATR (14) | 0.22 | Info |
The 30-day technical picture is bullish overall. RSI14 is 50, with near-term momentum balanced as of the latest reading. The 50-day moving average (SMA50) sits at $6.96, above the 200-day moving average (SMA200) at $5.48, which can be interpreted as a supportive tilt in the trend.
Key near-term levels include a support at $6.90 and a resistance at $8.34. The 30-day range spans from a low of $5.74 to a high of $9.11, highlighting a window of volatility within which the price could move in the short term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.57 | $7.59 | $11.44 | 0% | Neutral | |
| $9.45 | $12.22 | $16.87 | +61% | Bullish | |
| $10.63 | $14.24 | $20.52 | +88% | Bullish | |
| $11.11 | $15.32 | $22.85 | +102% | Bullish | |
| $12.85 | $18.20 | $27.94 | +140% | Bullish | |
| $13.55 | $19.67 | $30.95 | +159% | Bullish | |
| $14.81 | $21.99 | $35.38 | +190% | Bullish | |
| $18.96 | $28.76 | $47.21 | +279% | Bullish | |
| $23.09 | $35.75 | $59.79 | +371% | Bullish | |
| $25.52 | $40.31 | $68.58 | +431% | Bullish | |
| $36.51 | $63.18 | $115.48 | +732% | Bullish | |
| $65.53 | $133.53 | $270.65 | +16.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.57 | $7.59 | $8.91 | +0.00% |
| June 2026 | $6.41 | $7.57 | $9.19 | -0.22% |
| July 2026 | $6.62 | $7.90 | $9.75 | +4.36% |
| August 2026 | $6.58 | $7.92 | $9.89 | +0.21% |
| September 2026 | $6.44 | $7.81 | $9.86 | -1.37% |
| October 2026 | $6.75 | $8.23 | $10.49 | +5.39% |
| November 2026 | $7.14 | $8.75 | $11.25 | +6.34% |
| December 2026 | $7.17 | $8.84 | $11.44 | +0.94% |
Click any year to see its month-by-month DTIL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DTIL to range from $3.57 to $11.44 through 2026. The $7.59 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The DTIL price prediction for 2027 points to an average of $12.22 (low $9.45, high $16.87) — a potential gain of +61% on today's $7.59. Buyers look set to stay in control over this stretch.
In 2028, DTIL is projected to trade between $10.63 and $20.52, averaging $14.24 — a potential gain of +88% from today's $7.59. That is up +17% on the projected 2027 average. Momentum favours further upside here.
Precision BioSciences, Inc.'s 2029 outlook centres on $15.32, within a $11.11 to $22.85 range. That is up +8% on the projected 2028 average. That marks a +102% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, DTIL could reach as high as $27.94, with a base case around $18.20 and support toward $12.85 — roughly +140% from $7.59. Momentum favours further upside here.
Expect DTIL to range from $13.55 to $30.95 through 2031. The $19.67 average target implies a +159% move from current prices. That is up +8% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The DTIL price prediction for 2032 points to an average of $21.99 (low $14.81, high $35.38) — a potential gain of +190% on today's $7.59. Momentum favours further upside here.
In 2033, DTIL is projected to trade between $18.96 and $47.21, averaging $28.76 — a potential gain of +279% from today's $7.59. That is up +31% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Precision BioSciences, Inc.'s 2034 outlook centres on $35.75, within a $23.09 to $59.79 range. That is up +24% on the projected 2033 average. That marks a +371% change versus current levels. Momentum favours further upside here.
By 2035, DTIL could reach as high as $68.58, with a base case around $40.31 and support toward $25.52 — roughly +431% from $7.59. Buyers look set to stay in control over this stretch.
Expect DTIL to range from $36.51 to $115.48 through 2040. The $63.18 average target implies a +732% move from current prices. That is up +57% on the projected 2035 average. Momentum favours further upside here.
The DTIL price prediction for 2050 points to an average of $133.53 (low $65.53, high $270.65) — a potential gain of +16.6x on today's $7.59. Buyers look set to stay in control over this stretch.
Investing $1,000 in DTIL today (≈ 131.752306 DTIL) could be worth
$17,593.29
+$16,593.29 (+1659%) by 2050 · US Dollar
Based on the average projected DTIL price of $133.53 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DTILwould be worth at today's price.
$1,000 invested in DTIL on May 27, 2025 (≈ 204.498983 DTIL) would be worth
$1,552.15
+$552.15 (+55.2%) today · 1.55× · US Dollar
Based on a DTIL entry price of $4.89 vs. today's $7.59.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.18 | $1,057.1 | +5.7% |
| 1 month ago | $7.04 | $1,078.13 | +7.8% |
| 3 months ago | $3.99 | $1,902.26 | +90.2% |
| 6 months ago | $5.44 | $1,395.22 | +39.5% |
| 1 year ago | $4.89 | $1,552.15 | +55.2% |
| All time (5.0y) ago | $324.3 | $23.4 | -97.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DTIL forecast.
Our base-case forecast reaches $15.00 around 2029.
Implied market cap at $15.00: $387.03M
The multi-year forecast shows ongoing bullish sentiment with notable upside potential. By 2030, the average price is projected to be $16.30, representing a 125.4% ROI from the base or higher, depending on the entry point, and a continued upward trajectory in subsequent years.
The 2040 forecast envisions an average price of $50.37 with a 596.7% ROI, continuing the positive trend into 2050, where the average price is $104.43 and the ROI is 1344.4. These figures illustrate substantial long-term upside for investors who can endure extended horizon risk. The volatility reflected in the data—annualized at 70%—highlights the risk that actual results may deviate from the projections.
While sentiment remains bullish across the long horizon, these estimates are not guarantees and should be weighed against individual risk tolerance and market conditions.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $16.30 with a minimum of $11.45 and a maximum of $25.15; ROI is 125.4% and sentiment is BULLISH.
The forecast indicates bullish sentiment from 2027 onward, with the average price rising from $11.42 in 2027 to $104.43 by 2050 and notable ROIs (e.g., 58% in 2027, 81% in 2028, 90.2% in 2029, rising to 125.4% in 2030 and beyond). These are estimates and not guarantees.
The 2040 forecast lists an average price of $50.37 with a maximum of $92.79 and an ROI of 596.7%, indicating a potential approach to the $50 level by 2040 under the modeled scenario.
Current price is $7.23 per share and market cap is $186.55M.
The 30-day range is from $5.74 to $9.11, with a near-term support at $6.90 and resistance at $8.34.
Precision BioSciences, Inc. Community Discussion
0Share your Precision BioSciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.